IBM Watson, Illumina collaborate on cancer genetics decision-making - Pharmaphorum

IBM Watson Health's Watson for Genomics platform is to help inform cancer treatment decisions based on gene sequencing data from company Illumina. The artificial intelligence software will by applied to data from Illumina's TruSight Tumor 170 platform – a next generation sequencing gene panel that provides data related to 170 genes associated with common solid tumours. Watson will analyse the data alongside medical literature, clinical trial data and professional guidelines to help produce informed insights on how cancers could be treated. The entire process from raw genetic data to treatment insights will be completed in a matter of minutes – much quicker than the usual week or so it takes scientists to produce a similar report. "This partnership lays the groundwork for more systematic study of the impact of genomics in oncology," said Deborah DiSanzo, general manager, IBM Watson Health.